scispace - formally typeset
J

Jan Olaf Stracke

Researcher at Hoffmann-La Roche

Publications -  38
Citations -  1618

Jan Olaf Stracke is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Antibody & Monoclonal antibody. The author has an hindex of 19, co-authored 37 publications receiving 1368 citations.

Papers
More filters
Journal ArticleDOI

Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle

TL;DR: The Brain Shuttle module is developed, which can be engineered into a standard therapeutic antibody for successful BBB transcytosis and provides in vitro and in vivo evidence that the monovalent binding mode facilitates transcellular transport, whereas a bivalent binding mode leads to lysosome sorting.
Patent

Multispecific antibodies comprising full length antibodies and single chain fab fragments

TL;DR: In this paper, the present invention relates to multispecific, especially bispecific antibodies comprising full length antibodies and single chain Fab fragments, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
Journal ArticleDOI

Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies

TL;DR: Results demonstrate that FcRn affinity chromatography is a useful new method for the assessment of IgG integrity and correlates to changes in the PK profile in the F cRn transgenic mice.
Journal ArticleDOI

Simultaneous assessment of Asp isomerization and Asn deamidation in recombinant antibodies by LC-MS following incubation at elevated temperatures.

TL;DR: The here presented approach greatly facilitates the evaluation of fermentation, purification, formulation, and storage conditions on antibody asparagine deamidation and aspartate isomerization by monitoring susceptible marker peptides located in the complementary-determining regions of recombinant antibodies.
Journal ArticleDOI

Bispecific digoxigenin-binding antibodies for targeted payload delivery

TL;DR: Bispecific antibodies that bind cell-surface targets as well as digoxigenin (Dig) were generated for targeted payload delivery and complexes are targeted by the bispecifics to cancer cells and because these complexes are stable in serum, they can be applied for targeted delivery.